UNITED COMMUNITY BANKS INC
No enriched coverage for $UCB in the last 7 days.
No SEC Form 4 filings for $UCB in the last 30 days.
See all $UCB insider activity →United Community Banks (UCB) has scheduled its Q3 2026 earnings release for October 20. The stock has seen mixed performance, with a 6% YTD gain but a 6% drop over the past quarter. Analysts estimate a fair value of $39.83, suggesting a 16% undervaluation at the current price of $33.35. The bank's diversification efforts aim to stabilize earnings and mitigate risks.
UCB presented data at the EADV 2026 Congress showing earlier treatment with Bimzelx leads to higher resolution rates in hidradenitis suppurativa. At three years, 47.4% of early-treated patients achieved IHS4-100, compared to 33.3% of late-treated patients. Biotherapy-naive patients saw up to 78.8% complete resolution of draining tunnels. The company is expanding its presence beyond this condition.
Pharma companies Sanofi, UCB, and Opella have joined the Clean Heat Program to decarbonize manufacturing processes. The initiative aims to reduce industrial heat emissions, a major source of carbon output. Each company has SBTi-validated net-zero targets, with Sanofi and UCB aiming for 90% reductions by 2045, and Opella targeting 90% by 2050.
Recent UCB coverage spans financial news, regulation and sector analysis.
The earnings date announcement may prompt modest trading activity, with potential slight downside pressure as the stock has slipped 4% over the past month.
Positive trial data may lift UCB's stock as it supports the efficacy of bimekizumab.
UCB's ESG profile improves, which may attract sustainability‑focused capital.
No insider ownership change; likely no immediate price impact.
Significant UK investment could enhance UCB's pipeline and market perception.
AlphAI scores every news story that mentions UCB with an AI model for sentiment and relevance, and aggregates insider trades from UNITED COMMUNITY BANKS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
United Community Banks (UCB) has scheduled its Q3 2026 earnings release for October 20. The stock has seen mixed performance, with a 6% YTD gain but a 6% drop over the past quarter. Analysts estimate a fair value of $39.83, suggesting a 16% undervaluation at the current price of $33.35. The bank's diversification efforts aim to stabilize earnings and mitigate risks.
1 min readUCB presented data at the EADV 2026 Congress showing earlier treatment with Bimzelx leads to higher resolution rates in hidradenitis suppurativa. At three years, 47.4% of early-treated patients achieved IHS4-100, compared to 33.3% of late-treated patients. Biotherapy-naive patients saw up to 78.8% complete resolution of draining tunnels. The company is expanding its presence beyond this condition.
1 min readPharma companies Sanofi, UCB, and Opella have joined the Clean Heat Program to decarbonize manufacturing processes. The initiative aims to reduce industrial heat emissions, a major source of carbon output. Each company has SBTi-validated net-zero targets, with Sanofi and UCB aiming for 90% reductions by 2045, and Opella targeting 90% by 2050.
2 min readUnited Community Banks (UCB) CFO Speir Thomas Hardaway filed an initial statement of beneficial ownership, reporting no shares of UCB Common Stock. The filing indicates zero beneficial ownership of UCB's common stock as of the filing date.
1 min readPharmaceutical companies invested £1.98bn in the UK since September 2025, per ABPI. Government support, including NICE threshold increases and UK–US trade deal, aided this. AstraZeneca, UCB, Accord, and Boehringer Ingelheim made notable commitments. ABPI warns recovery is fragile due to competitiveness and clinical trial delays.
2 min readUNITED COMMUNITY BANKS INC (UCB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release For more information: Tom Speir Chief Financial Officer (864) 240-6208 Tom_Speir@ucbi.com United Community Banks, Inc. Announces Completion of Strategic Initiatives That Simplify and Strengthen Balance Sheet; Increased Share Repurchase Authoriza
2 min readPresident Trump expanded drug-pricing agreements with 9 international companies, including Alcon and Teva, adding to 17 prior deals with firms like Pfizer. The MFN framework now covers 89% of the branded drug market. The impact on healthcare ETFs is mixed, with potential benefits for insurers (IHF) and uncertain effects on U.S. pharma (PPH).
3 min readPresident Trump secured drug pricing agreements with nine pharma firms, including Alcon, Astellas, Teva, and UCB, bringing the total to 26 firms representing 90% of the US market. The deals require Medicaid discounts and $19.6B in US manufacturing investments. The White House estimates $529B in economic savings over a decade.
3 min readUnited Community Banks (UCB) granted its chief accounting officer, Alan H. Kumler, 2,932 restricted stock units (RSUs) on September 1, 2026. These RSUs vest in four equal installments from 2027 to 2030. Kumler now directly holds 23,612 shares of the company's common stock. The grant was not made under a Rule 10b5-1 trading plan.
1 min readNine drugmakers (Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, UCB) joined Medicaid pricing deals, covering 89% of branded drug market. Savings estimated at $600B over a decade, per the White House. Medicaid copays likely unchanged. Companies to invest $19.6B in U.S. manufacturing and donate drug ingredients.
3 min read
